BACKGROUND: Major incompatible platelet (PLT) transfusions have been associated with inferior posttransfusion PLT count increments compared with ABO-compatible transfusions. However, most studies to date have been small and involved hematology/oncology patients. STUDY DESIGN AND METHODS: We conducted a prospective observational study in predominantly nononcologic patients to determine whether ABO-compatible (defined as ABO identical and minor incompatible) PLT transfusions resulted in superior posttransfusion PLT count increments. We collected data on consecutive inpatients at Hamilton General Hospital receiving a PLT transfusion during a 50-month period. We compared the absolute count increment (ACI) and corrected count increment (CCI) values in ABO-compatible versus incompatible PLT transfusions. Linear regression was performed to adjust for factors potentially affecting the posttransfusion PLT count response. Univariate models were applied to each explanatory variable with p values of less than 0.10 considered potentially significant. Multivariate models were applied to all potential explanatory variables of interest. p values of less than 0.05 were considered significant. RESULTS: A total of 1030 transfusions were included in the primary analysis, 73.7% of which were ABO compatible. The median ACI was 35 (interquartile range [IQR], 18-55) for compatible transfusions versus 31 (IQR, 13-51) for incompatible transfusions (p = 0.1480). The median posttransfusion CCI (n = 686) was 18.6 (IQR, 10.2-28.4) for compatible transfusions versus 15.2 (IQR, 4.7-25.7) for incompatible transfusions (p = 0.0499). CONCLUSIONS: ABO-compatible transfusions in nononcologic patients are associated with a significantly better CCI although the observed difference is small (approx. 20%) and may not be clinically significant.
BACKGROUND: Major incompatible platelet (PLT) transfusions have been associated with inferior posttransfusion PLT count increments compared with ABO-compatible transfusions. However, most studies to date have been small and involved hematology/oncology patients. STUDY DESIGN AND METHODS: We conducted a prospective observational study in predominantly nononcologic patients to determine whether ABO-compatible (defined as ABO identical and minor incompatible) PLT transfusions resulted in superior posttransfusion PLT count increments. We collected data on consecutive inpatients at Hamilton General Hospital receiving a PLT transfusion during a 50-month period. We compared the absolute count increment (ACI) and corrected count increment (CCI) values in ABO-compatible versus incompatible PLT transfusions. Linear regression was performed to adjust for factors potentially affecting the posttransfusion PLT count response. Univariate models were applied to each explanatory variable with p values of less than 0.10 considered potentially significant. Multivariate models were applied to all potential explanatory variables of interest. p values of less than 0.05 were considered significant. RESULTS: A total of 1030 transfusions were included in the primary analysis, 73.7% of which were ABO compatible. The median ACI was 35 (interquartile range [IQR], 18-55) for compatible transfusions versus 31 (IQR, 13-51) for incompatible transfusions (p = 0.1480). The median posttransfusion CCI (n = 686) was 18.6 (IQR, 10.2-28.4) for compatible transfusions versus 15.2 (IQR, 4.7-25.7) for incompatible transfusions (p = 0.0499). CONCLUSIONS:ABO-compatible transfusions in nononcologic patients are associated with a significantly better CCI although the observed difference is small (approx. 20%) and may not be clinically significant.
Authors: Julie Sahler; Katie Grimshaw; Sherry L Spinelli; Majed A Refaai; Richard P Phipps; Neil Blumberg Journal: Drug Discov Today Dis Mech Date: 2011-07-20
Authors: Marianne E Nellis; Ruchika Goel; Oliver Karam; Melissa M Cushing; Peter J Davis; Marie E Steiner; Marisa Tucci; Simon J Stanworth; Philip C Spinella Journal: Pediatr Crit Care Med Date: 2019-02 Impact factor: 3.624
Authors: Moritz Stolla; Majed A Refaai; Joanna M Heal; Sherry L Spinelli; Olivier Garraud; Richard P Phipps; Neil Blumberg Journal: Front Immunol Date: 2015-02-02 Impact factor: 7.561